Gene-Based Therapeutics for Parkinson’s Disease

Karim E. Shalaby, Omar M.A. El-Agnaf*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)

Abstract

Parkinson’s disease (PD) is a complex multifactorial disorder that is not yet fully surmised, and it is only when such a disease is tackled on multiple levels simultaneously that we should expect to see fruitful results. Gene therapy is a modern medical practice that theoretically and, so far, practically, has demonstrated its capability in joining the battle against PD and other complex disorders on most if not all fronts. This review discusses how gene therapy can efficiently replace current forms of therapy such as drugs, personalized medicine or invasive surgery. Furthermore, we discuss the importance of enhancing delivery techniques to increase the level of transduction and control of gene expression or tissue specificity. Importantly, the results of current trials establish the safety, efficacy and applicability of gene therapy for PD. Gene therapy’s variety of potential in interfering with PD’s pathology by improving basal ganglial circuitry, enhancing dopamine synthesis, delivering neuroprotection or preventing neurodegeneration may one day achieve symptomatic benefit, disease modification and eradication.

Original languageEnglish
Article number1790
JournalBiomedicines
Volume10
Issue number8
DOIs
Publication statusPublished - Aug 2022

Keywords

  • Parkinson’s disease
  • gene therapy
  • neurodegeneration

Fingerprint

Dive into the research topics of 'Gene-Based Therapeutics for Parkinson’s Disease'. Together they form a unique fingerprint.

Cite this